AbbVie showcases its leadership in Rheumatology research with new data across multiple inflammatory joint diseases

The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually

Roche’s Gazyva shows breakthrough efficacy in phase III lupus study

The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25